Viridian Therapeutics(US:VRDN) ZACKS·2026-02-26 16:01分组1 - Viridian Therapeutics reported a quarterly loss of $1.08 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.90, and compared to a loss of $0.81 per share a year ago, indicating an earnings surprise of -20.67% [1] - The company posted revenues of $0.13 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 99.29%, and this was an increase from revenues of $0.07 million a year ago [2] - The stock has underperformed the market, losing about 7% since the beginning of the year, while the S&P 500 gained 1.5% [3] 分组2 - The earnings outlook for Viridian Therapeutics is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for Viridian Therapeutics was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market in the near future [6] - The current consensus EPS estimate for the upcoming quarter is -$0.98 on $0.1 million in revenues, and for the current fiscal year, it is -$3.50 on $88.07 million in revenues [7] 分组3 - The Medical - Biomedical and Genetics industry, to which Viridian Therapeutics belongs, is currently in the top 36% of over 250 Zacks industries, indicating a favorable outlook for stocks in this sector [8]